Frequently asked questions
This section covers all the questions that we were asked during the OMC. It will be updated regularly with answers to your questions.
Tenders that receive public funding from other sources will be excluded if this leads to double public financing or an accumulation of different types of public financing that is not permitted by EU legislation, including EU state aid rules. Compliance needs to be confirmed in a dedicated section of the Declaration of Honour on on/off Award Criteria when submitting a tender.
Experts from different backgrounds such as clinical, technical, project management, commercialization, etc. from all procurers.
A private hospital can be a supplier. It cannot be an end user since the only end users in the project are the procurers.
Risks always exist in R&D projects. However, in INCAREHEART they will be minimised with the clear definition of work and close collaboration between the procurers and suppliers.
Please see and feel free to fill in the matchmaking questionnaire on our project website.
Yes.
Each phase has a ceiling budget per expected number of suppliers. The suppliers are free to place their price offers that do not exceed the ceiling.
Note that Horizon 2020 requires PCP procurements to cover three R&D phases that cover solution exploration and design, prototyping, original development, and validation/testing of a limited volume of first products or services in the form of a test series.
We expect TRL8 at the end of phase 3. It is important to note that the procurers in PCPs may also be interested in buying (yet through another subsequent procedure) commercial volumes of the innovative solutions. It is therefore important that suppliers could perform (e.g., in parallel with PCP) the actions (e.g., certification/labelling/IPR protection) that are necessary for the commercial roll out of the innovative solutions.
No. PCP does not guarantee large scale procurement.
The Framework Agreement may have clauses that remain binding after the duration of the project, e.g., about confidentiality, IPR, etc.
